ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill combo aims to fight stomach cancer when first treatment fails
Disease control Recruiting nowThis study tests whether taking oral paclitaxel plus fruquintinib can help people with advanced stomach or gastroesophageal junction cancer after their first treatment stops working. About 150 adults will receive either the new drug combo or standard chemotherapy chosen by their …
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: NA • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
Could an immunotherapy boost help fight stomach cancer?
Disease control Recruiting nowThis clinical trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) can help people with advanced stomach or esophageal cancer live longer. The study includes 224 adults whose cancer has a specific marker (PD-L1 CPS…
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 02, 2026 01:00 UTC
-
New drug cocktail aims to fight tough stomach cancer
Disease control Recruiting nowThis Phase 3 trial tests a new drug called JS107 combined with toripalimab and chemotherapy against a standard treatment for advanced stomach cancer that has a specific marker (CLDN18.2). The study plans to enroll 600 people whose cancer has spread and cannot be removed by surger…
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: NingBo Junyan Hongshi Biosciences Co., Ltd • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New chemo combo tested to extend life in Hard-to-Treat stomach and esophageal cancers
Disease control Recruiting nowThis study tests whether a stronger chemotherapy mix (mFOLFIRINOX) works better than the standard mix (FOLFOX) for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. Some participants also receive the immunotherapy dru…
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Engineered immune cells take on stomach cancer in early trial
Disease control Recruiting nowThis study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two proteins found on stomach cancer cells. The therapy is given to adults with advanced stomach or gastroesophageal junction cancer that has not responded to standard treatments. Th…
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Beijing Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for advanced stomach cancer: drug combo targets patients who failed first-line therapy
Disease control Recruiting nowThis study tests a combination of two drugs, carilizumab and albumin paclitaxel, as a second treatment for people with advanced stomach cancer. It includes 40 adults aged 18-75 who have already tried one prior treatment, with or without immunotherapy. The goal is to see if this c…
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Shandong Tumor Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New hope for advanced stomach cancer: drug combo aims to extend survival
Disease control Recruiting nowThis study tests whether a combination of two drugs (camrelizumab and apatinib) can help people with advanced stomach or gastroesophageal junction cancer live longer compared to standard chemotherapy. The trial includes 550 adults whose cancer progressed after first-line platinum…
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New drug cocktail aims to shrink advanced stomach tumors
Disease control Recruiting nowThis early-phase trial is testing whether combining two drugs—pembrolizumab (an immunotherapy that helps the immune system attack cancer) and lenvatinib (which blocks enzymes that help tumors grow)—can shrink tumors in people with advanced stomach or gastroesophageal cancer that …
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: EARLY_PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Cancer care at home: a game changer for patients?
Symptom relief Recruiting nowThis study compares giving cancer treatment at home versus in the clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves overall experience. About 220 participants will be randomly assigned to receive their reg…
Matched conditions: ADVANCED GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jun 27, 2026 12:10 UTC